Table 2. Cancer Risks for Ranitidine Users Compared With Other H2 Receptor Antagonist (H2RA) Users.
| Outcomes | Incidence, events per 1000 PYs | HR (95% CI) | Raw P value | Corrected P valueb | ||
|---|---|---|---|---|---|---|
| Ranitidine | Other H2RAs | Uncalibrated | Calibrateda | |||
| All cancers excluding nonmelanoma skin cancer | 15.92 | 15.65 | 1.04 (0.97-1.12) | 1.02 (0.94-1.10) | ||
| All cancers | 18.11 | 17.82 | 1.04 (0.97-1.13) | 1.02 (0.94-1.10) | .24 | >.99 |
| All cancers, excluding thyroid cancer | 17.74 | 17.44 | 1.05 (0.97-1.12) | 1.02 (0.94-1.10) | .21 | >.99 |
| Breast cancer | 1.85 | 2.01 | 0.84 (0.69-1.02) | 0.82 (0.67-0.99) | .08 | >.99 |
| Prostate cancer | 1.83 | 1.87 | 0.98 (0.90-1.07) | 0.96 (0.87-1.05) | .68 | >.99 |
| Lung cancer | 1.45 | 1.36 | 1.07 (0.97-1.17) | 1.04 (0.94-1.14) | .17 | >.99 |
| Colorectal cancer | 1.12 | 1.11 | 1.00 (0.90-1.11) | 0.97 (0.87-1.08) | .95 | >.99 |
| Bladder cancer | 0.59 | 0.59 | 0.89 (0.68-1.16) | 0.87 (0.66-1.13) | .40 | >.99 |
| Liver cancer | 0.59 | 0.58 | 1.00 (0.86-1.15) | 0.97 (0.84-1.12) | .95 | >.99 |
| Leukemia | 0.52 | 0.54 | 1.12 (0.77-1.63) | 1.09 (0.75-1.59) | .56 | >.99 |
| Pancreatic cancer | 0.50 | 0.51 | 0.97 (0.79-1.18) | 0.94 (0.77-1.15) | .75 | >.99 |
| Stomach cancer | 0.37 | 0.29 | 1.17 (0.88-1.54) | 1.13 (0.86-1.50) | .28 | >.99 |
| Lip, oral cavity, and pharynx cancer | 0.27 | 0.28 | 1.00 (0.76-1.33) | 0.98 (0.74-1.30) | .97 | >.99 |
| Thyroid cancer | <0.44c | <0.44c | 1.01 (0.85-1.19) | 0.98 (0.83-1.16) | .93 | >.99 |
| Corpus uteri cancer | <0.34c | 0.28 | 1.20 (0.95-1.52) | 1.17 (0.92-1.48) | .13 | >.99 |
| Ovary cancer | <0.26c | <0.21c | 1.26 (1.00-1.58) | 1.22 (0.97-1.54) | .05 | .88 |
| Esophageal cancer | <0.16c | 0.15 | 1.08 (0.82-1.43) | 1.05 (0.79-1.40) | .59 | >.99 |
| Gallbladder and biliary tract cancer | <0.16c | 0.14 | 1.14 (0.86-1.53) | 1.11 (0.83-1.49) | .36 | >.99 |
| Cervix uteri cancer | <0.11c | <0.13c | 0.88 (0.64-1.22) | 0.86 (0.62-1.19) | .45 | >.99 |
Abbreviations: HR, hazard ratio; PY, person-year.
a
HRs and 95% CIs were empirically calibrated based on the results from the negative control outcome to address systematic bias.
b
P values were adjusted using the Bonferroni correction for multiple comparisons. The Bonferroni-corrected P value for multiple comparisons was not calculated for a single primary outcome.
c
If the number of outcomes was less than the prespecified minimum count (n = 5), the exact number was masked before aggregation to minimize the reidentification risk of a patient.